Related references
Note: Only part of the references are listed.Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
W. Joseph Herring et al.
ALZHEIMERS & DEMENTIA (2020)
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
Yves Dauvilliers et al.
ANNALS OF NEUROLOGY (2020)
Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo
Timothy A. Roehrs et al.
JOURNAL OF CLINICAL SLEEP MEDICINE (2020)
Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis
Taro Kishi et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2020)
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder
Gary Zammit et al.
NEUROLOGY (2020)
Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
Mikko Karppa et al.
SLEEP (2020)
Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER-1 study
Kazuomi Kario et al.
JOURNAL OF CLINICAL HYPERTENSION (2019)
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
Kasper Recourt et al.
TRANSLATIONAL PSYCHIATRY (2019)
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
Sander Brooks et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder A Phase 3 Randomized Clinical Trial
Russell Rosenberg et al.
JAMA NETWORK OPEN (2019)
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
Peter De Boer et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study
Thomas Roth et al.
SLEEP (2017)
Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study
Thomas Roth et al.
SLEEP (2017)
Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
Kathryn M. Connor et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2017)
Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference
Jed Black et al.
SLEEP MEDICINE (2017)
Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis
Akira Kuriyama et al.
SLEEP MEDICINE REVIEWS (2017)
Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders
Fiona Auld et al.
SLEEP MEDICINE REVIEWS (2017)
Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians
Timothy J. Wilt et al.
ANNALS OF INTERNAL MEDICINE (2016)
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
W. Joseph Herring et al.
BIOLOGICAL PSYCHIATRY (2016)
A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia
Kathryn M. Connor et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis
Almira Chabi et al.
CEPHALALGIA (2015)
Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists
Yu Yoshida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial
David Michelson et al.
LANCET NEUROLOGY (2014)
Hypocretin (orexin) regulation of sleep-to-wake transitions
Luis de Lecea et al.
FRONTIERS IN PHARMACOLOGY (2014)
Insomnia
Daniel J. Buysse
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
P. Hoever et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Orexin receptor antagonism for treatment of insomnia A randomized clinical trial of suvorexant
W. Joseph Herring et al.
NEUROLOGY (2012)
Prevalence and Perceived Health Associated with Insomnia Based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition Criteria: Results from the America Insomnia Survey
Thomas Roth et al.
BIOLOGICAL PSYCHIATRY (2011)
Insomnia and the Risk of Acute Myocardial Infarction A Population Study
Lars E. Laugsand et al.
CIRCULATION (2011)
Nighttime Insomnia Symptoms and Perceived Health in the America Insomnia Survey (AIS)
James K. Walsh et al.
SLEEP (2011)
Insomnia and the Performance of US Workers: Results from the America Insomnia Survey
Ronald C. Kessler et al.
SLEEP (2011)
The Natural History of Insomnia A Population-Based 3-Year Longitudinal Study
Charles M. Morin et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
The efficacy and safety of drug treatments for chronic insomnia in adults: A meta-analysis of RCTs
Nina Buscemi et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2007)
Promotion of sleep by targeting the orexin system in rats, dogs and humans
Catherine Brisbare-Roch et al.
NATURE MEDICINE (2007)
Share Paper
